Navigation Links
Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
Date:10/31/2007

r the comparable period of 2006. The ratio of cost of sales to net sales was stable year-on-year, with the impact of generic competition for Ambien(R) IR partly offset by a better product mix. Other revenues, at euro 845 million, were down on the 2006 9-month figure (euro 888 million), due largely to the discontinuation of royalty income on fipronil.

Research and development expenses rose by 1.5% (4.4% excluding the effect of exchange rates).

Over the first nine months of 2007, the cost adaptation measures initiated in 2006 helped to reduce the ratio of selling and general expenses to net sales to 26.3%, 1.6 points lower than in the comparable period of 2006. Selling and general expenses for the nine-month period were euro 5,558 million, a reduction of 5.3%, with selling expenses and general expenses falling in equal proportions.

Other current operating income (net of expenses) totaled euro 200 million, versus euro 236 million in the comparable period of 2006, and included an expense of euro 61 million (euro 42 million after tax) on the harmonization of welfare and healthcare plans for the Group's retirees.

Operating income -- current rose by 4.1%, and represented 36.2% of net sales compared with 35.0% in the first nine months of 2006.

A restructuring charge of euro 50 million (euro 35 million after tax) has been recognized in connection with the ongoing adaptation plan initiated in France in 2006.

In the comparable period of 2006, the financial statements included gains on disposal of euro 553 million, mainly on the sale of the Exubera(R) rights (euro 460 million, or euro 384 million after tax) and the sale of the residual stake in the Animal Nutrition business (euro 45 million, or euro 31 million after tax).

Net financial expense was euro 111 million, against euro 146 million in the comparable period of 2006. Interest expense on debt was euro 176 million, compared with euro 250 million in the nine months to end September 2
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Sanofi-Aventis Allows Thais To Make Plavix
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... This past August, Narconon Louisiana New Life Retreat ... kissing booth during the West Feliciana Animal Humane Society fundraiser to ... loved animals my whole life and have always had animals as ... who needed a home. Supporting an animal shelter allows me ... home!” , The CEO of Narconon Louisiana was there not only ...
(Date:9/18/2014)... NC (PRWEB) September 18, 2014 Relias Learning, ... health and human services markets, today announced it has been ... fastest growing private companies in America. , In the three-year ... and moved up almost 2,000 spots on the Inc. 5000 ... 2012. , “The industries we serve continue to ...
(Date:9/18/2014)... September 18, 2014 The new ... boon to contractors and homeowners alike as it ... overtakes the home, causes potential health issues, and ... nationwide, the BuildClean system allows contractors to virtually ... and other standard remodeling tasks. , BuildClean removes ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, Sept. ... be associated with increased odds of developing Parkinson,s disease ... suggests. The study, which did not prove a ... that the migraine-Parkinson,s association was stronger in women with ... sign of a pending attack that includes flashes of ...
(Date:9/18/2014)... 2014 It is true that ... when building a successful brand or business online. ... has recently compared plenty of professional web hosting ... Arvixe and iPage are the best VPS hosting ... of web hosting. All-sized businesses or enterprises can ...
Breaking Medicine News(10 mins):Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3Health News:Best Cheap Hosting USA: GreenGeeks, Arvixe And iPage Are The Best Hosting Suppliers In 2014 2
... Bolling Air Force Base in Washington D.C., as well as a lecture ... ... Washington, D.C. (Vocus) July 2, 2008 -- The Drug Enforcement Administration ... Richard Nixon, who through an Executive Order established a single unified command ...
... QuadraBloc™, a new and improved version of AmWay's MagnaBloc. , ... ... a long-popular form of pain management, is now available in a ... ,"QuadraBloc has already been released in the United States, and will ...
... will be October 24-26, 2008 at the Catholic Institute in Toulouse, ... knowledge, ideas, applications and prospective issues in an interactive and collaborative ... http://www.ifats08.org for details. , ... Carmel, IN (PRWEB) ...
... using a combination of drugs targeting different parts of ... with severe lupus involving the kidneys, according to a ... Society of Nephrology (JASN). , "In our study, ... therapy for inducing complete remission of class V+IV lupus ...
... Clearance of Uniquely Integrated Meter/Pump System with ... and Compatible Software, WEST CHESTER, Pa., July ... its OneTouch(R) Ping(TM) Glucose Management System,by the U.S. ... the first,full-feature insulin pump that wirelessly communicates with ...
... of 300 human genomes in just over six months. The ... of genetic code that will be read by researchers worldwide, ... and disease. Scientists will be able to answer questions unthinkable ... be transformed. , The amount of data is remarkable: ...
Cached Medicine News:Health News:New MagnaBloc™ Product Available from Gradient Medical 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 3Health News:'Multi-target' immune therapy improves outcomes of severe lupus nephritis 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 3Health News:15 human genomes each week 2Health News:15 human genomes each week 3
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert ... Canada , released today by the ... safe and effective medicines for children. Each year about ... children use at least one prescription drug. Much of ... from the authorized use), creating potential health risks. ...
(Date:9/18/2014)... 18, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that the Company,s President ... Cauwenbergh , will present at the 7 ... Wednesday, September 24, 2014 at 11:20 a.m. ...
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, ... VVUS ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved a supplemental new drug application ... only FDA-approved erectile dysfunction (ED) medication indicated to be taken ... STENDRA is a prescription medication in a class of ...
Breaking Medicine Technology:Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9
... , , ... external defibrillators used worldwide in health care facilities, public places, or in the home may ... Administration warned today. , , , ... , , ...
... STOCKHOLM , April 27, 2010 Axelar AB, ... been,elected new chairman of the board and Ingemar Kihlstrom board ... , , ... have just secured 25 MSEK financing for the continued development of,Axelar,s anticancer ...
Cached Medicine Technology:FDA Warns Users About Faulty Components in 14 External Defibrillator Models 2FDA Warns Users About Faulty Components in 14 External Defibrillator Models 3Axelar's Board Strengthened 2Axelar's Board Strengthened 3
... 4.5x and 5.5x magnification., ,Higher magnification ... guarantees a true image. Edge to ... is ideal for intricate surgical applications. ... with an anti-reflective coating to produce ...
VACUETTE® Tube Holders should be used exclusively with VACUETTE® Blood Collection Needles as both components are designed for optimal compatibility with one another....
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Medicine Products: